Chijioke C. Nze

Hematology | Oncology

210 Ashville Ave # 408
Cary, NC 27518

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma.

Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma.

Journal: Blood cancer journal

Published: January 27, 2026

Safety of concurrent radiation therapy with the antibody-drug conjugate polatuzumab vedotin in relapsed or refractory aggressive B-cell lymphomas.

Safety of concurrent radiation therapy with the antibody-drug conjugate polatuzumab vedotin in relapsed or refractory aggressive B-cell lymphomas.

Journal: Practical radiation oncology

Published: January 07, 2026

Assessing patient perspectives on enrollment in lymphoma clinical trials.

Assessing patient perspectives on enrollment in lymphoma clinical trials.

Journal: Cancer

Published: December 28, 2025

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Journal: Hematology. American Society of Hematology. Education Program

Published: December 05, 2025

Clinical trial access after CAR T-cell therapy failure in relapsed/refractory large B-cell lymphoma.

Clinical trial access after CAR T-cell therapy failure in relapsed/refractory large B-cell lymphoma.

Journal: British journal of haematology

Published: October 12, 2025

Multi-Institutional Study of ALK-Positive Large B-Cell Lymphoma: Outcomes in the Era of ALK Inhibitors and Biologically Informed Therapies.

Multi-Institutional Study of ALK-Positive Large B-Cell Lymphoma: Outcomes in the Era of ALK Inhibitors and Biologically Informed Therapies.

Journal: American journal of hematology

Published: June 20, 2025

Clinical Outcomes and Patterns of Care Among Patients With Newly Diagnosed Classical Hodgkin Lymphoma in a Safety-Net Health System.

Clinical Outcomes and Patterns of Care Among Patients With Newly Diagnosed Classical Hodgkin Lymphoma in a Safety-Net Health System.

Journal: Clinical lymphoma, myeloma & leukemia

Published: May 12, 2025

Impact of sociodemographic determinants on enrollment into contemporary lymphoma clinical trials: a systematic review.

Impact of sociodemographic determinants on enrollment into contemporary lymphoma clinical trials: a systematic review.

Journal: The oncologist

Published: November 25, 2024

Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas.

Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas.

Journal: Frontiers in immunology

Published: October 25, 2024

New strategies for enhancing enrollment of underrepresented minorities in lymphoma clinical trials.

New strategies for enhancing enrollment of underrepresented minorities in lymphoma clinical trials.

Journal: Blood advances

Published: July 12, 2024

Addressing Health Disparities in Hematologic Malignancies: from Genes to Outreach.

Addressing Health Disparities in Hematologic Malignancies: from Genes to Outreach.

Journal: Blood cancer discovery

Published: July 11, 2024

Clinical outcomes of patients with newly diagnosed large B-cell lymphoma in a safety-net hospital system.

Clinical outcomes of patients with newly diagnosed large B-cell lymphoma in a safety-net hospital system.

Journal: Blood neoplasia

Published: March 25, 2024

Showing 1-12 of 21

Last Updated: 09/26/2026